Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground

Key Points

• Elanco reported 10% quarterly growth and is targeting mid-single-digit revenue growth, high-single-digit EBITDA growth and low-double-digit EPS growth over the next three years, while generating $1 billion in cash through 2028.
• Quattro and Zenrelia are gaining rapid adoption across parasite and dermatology markets, with international expansion expected to support growth through 2027; Befrena could also become a major driver once supply capacity increases.
• Elanco plans to reduce leverage from roughly six-to-seven times after the Bayer acquisition to about three times by year-end and the two-times range next year, while improving margins and prioritizing debt reduction over major acquisitions.

Elanco Animal Health NYSE: ELAN President and CEO Jeff Simmons outlined the company’s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London.

Simmons said Elanco delivered 10% reported growth in its most recently completed quarter, split evenly between Farm Animal and Pet Health, as well as between U.S. and international markets and price and volume. He characterized the performance as “high-quality growth” and said the company remains focused on three priorities: growth, innovation and cash generation.

Elanco is targeting mid-single-digit revenue growth, high-single-digit EBITDA growth and low-double-digit earnings-per-share growth over the next three years, according to Simmons. The company has also committed to generating $1 billion in cash through 2028, expanding margins annually and reducing leverage.

Simmons said Elanco’s leverage, which reached roughly six to seven times following its acquisition of Bayer’s animal health business, is expected to decline to about three times by year-end and move into the two-times range next year.

Pricing and pet-health demand

Addressing pricing concerns in animal health, Simmons said Elanco recorded 2% pricing growth in the first half of the year and saw price gains accelerate in July and August. He said the company’s ability to raise prices is tied to medical differentiation, particularly for products addressing conditions important to pet owners.

Elanco surveyed 1,400 U.S. pet owners at the end of May, and 86% said they expected to spend the same amount or more on pet health, according to Simmons. While consumers may reduce spending on food, supplements and hard goods, he said the company has not seen a comparable pullback in spending on health-related products.

Simmons said the company sees no broad price war in the industry, though targeted promotions occur, especially among corporate veterinary groups. Elanco is underrepresented with corporate clinic groups, he said, but does not view that channel as necessary to drive its growth plan in the near term.

He also highlighted Elanco’s over-the-counter presence from the Bayer acquisition. The company sells through retailers and online platforms including Chewy, Amazon and Walmart, which Simmons said provides access to pet owners who do not regularly visit veterinarians and may be more price-sensitive.

Quattro and Zenrelia launch progress

Simmons identified Quattro, Elanco’s parasite treatment for dogs, as a major growth opportunity. He said the product has reached more than half of U.S. veterinary clinics and has become the fastest blockbuster product in Elanco’s history. The company has said Quattro has exceeded $100 million in sales.

Quattro is positioned in a $6 billion parasite market, including a $2 billion oral-treatment segment, Simmons said. He attributed its uptake to its four active ingredients, broad parasite coverage, tick-killing performance, first-month heartworm control and palatability. Elanco expects to begin expanding Quattro internationally, including a planned launch in the U.K. and Europe next year, which Simmons said should contribute to growth in 2027.

In dermatology, Simmons said Zenrelia has gained share in the approximately $2.5 billion market for treatments of itching dogs. The product is now used in more than half of U.S. clinics, with 40% of users prescribing it as a first-line treatment, according to Simmons. Elanco is adding roughly 400 to 500 clinics per month, he said.

The company has launched Zenrelia in roughly 45 countries. Simmons said Elanco gained 10 percentage points of market share in Europe during the first half, compared with two points for a newly launched competitor.

Elanco is also introducing Befrena, a monoclonal antibody treatment for canine dermatology. Simmons said U.S. veterinarians have shown demand exceeding available supply, and Elanco is increasing manufacturing capacity. The company expects to have full supply during the first half of next year, making Befrena a potential U.S. growth driver in 2027.

• Zenrelia and Befrena address the dermatology market through different treatment formats.
• Quattro’s global rollout is expected to add to Elanco’s 2027 growth drivers.
• Elanco has 15 projects in clinical development and expects five to six to advance to market between now and 2031.

Farm animal business and capital priorities

Simmons said Farm Animal remains a significant part of Elanco’s portfolio, representing about half of the company’s business. He said industry demand for animal protein has supported farm-animal health markets, citing growth in chicken and dairy production as well as consumer interest in protein, wellness and muscle retention.

Elanco expects Farm Animal revenue to grow at a strong mid-single-digit rate over the remainder of the decade, Simmons said. The company is a U.S. leader in poultry and cattle, while vaccines represent an area where it is underrepresented relative to the broader industry and sees room for investment.

The company recently acquired AHV, a Netherlands-based nutritional health company for cattle. Simmons said Elanco may pursue additional tuck-in opportunities but does not anticipate large acquisitions. Its capital allocation priority remains debt reduction, followed by potential shareholder-return actions and opportunistic investments.

Elanco’s margin plan calls for gross margin to rise from the mid-50% range toward 60%, while EBITDA margin is expected to advance from the low-20% range toward 30%. Simmons said about 75% of EBITDA margin expansion is expected to come from gross-margin improvement, including procurement, manufacturing utilization and footprint efficiency.

“We have a lot of runway of growth with stuff that’s already approved that’s globalizing,” Simmons said, pointing to the company’s dermatology, parasite and farm-animal product opportunities.

About Elanco Animal Health (NYSE:ELAN)

Elanco Animal Health Incorporated NYSE: ELAN is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company's products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.